Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Highlights
Tuberculosis (TB) complicating HIV-1 infection is a persistent significant clinical concern, in resource limited settings
Rifampicin may reduce EFV concentrations, little is known of the effect of the HIV virus or efavirenz on the pharmacokinetics of rifampicin, in resource limited settings where the burden of disease exists
We aimed to develop a low-cost, simple analytical method for the accurate determination of efavirenz and rifampicin plasma concentrations
Summary
Tuberculosis (TB) complicating HIV-1 infection is a persistent significant clinical concern, in resource limited settings. Treatment of HIV-infected patients with TB often comprises efavirenz-containing antiretroviral regimens when on TB treatment containing rifampicin. Rifampicin may reduce EFV concentrations, little is known of the effect of the HIV virus or efavirenz on the pharmacokinetics of rifampicin, in resource limited settings where the burden of disease exists. We aimed to develop a low-cost, simple analytical method for the accurate determination of efavirenz and rifampicin plasma concentrations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
